MX2018011225A - Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer. - Google Patents
Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer.Info
- Publication number
- MX2018011225A MX2018011225A MX2018011225A MX2018011225A MX2018011225A MX 2018011225 A MX2018011225 A MX 2018011225A MX 2018011225 A MX2018011225 A MX 2018011225A MX 2018011225 A MX2018011225 A MX 2018011225A MX 2018011225 A MX2018011225 A MX 2018011225A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- peptides
- present description
- cell receptors
- relates
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 108091008874 T cell receptors Proteins 0.000 title abstract 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 201000011510 cancer Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4268—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662308975P | 2016-03-16 | 2016-03-16 | |
| GBGB1604492.7A GB201604492D0 (en) | 2016-03-16 | 2016-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
| PCT/EP2017/056260 WO2017158103A1 (en) | 2016-03-16 | 2017-03-16 | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011225A true MX2018011225A (es) | 2018-11-22 |
Family
ID=55952417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011225A MX2018011225A (es) | 2016-03-16 | 2017-03-16 | Celulas t transfectadas y receptores de celulas t de utilidad en inmunoterapias contra el cancer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10538573B2 (enExample) |
| EP (1) | EP3430030B1 (enExample) |
| JP (1) | JP7340127B2 (enExample) |
| KR (2) | KR102457504B1 (enExample) |
| CN (1) | CN108884136B (enExample) |
| AU (2) | AU2017235467B2 (enExample) |
| CA (1) | CA3017502A1 (enExample) |
| CR (1) | CR20180492A (enExample) |
| EA (1) | EA201892021A1 (enExample) |
| GB (1) | GB201604492D0 (enExample) |
| MA (2) | MA43720A (enExample) |
| MX (1) | MX2018011225A (enExample) |
| MY (1) | MY189042A (enExample) |
| SG (1) | SG11201807868VA (enExample) |
| TW (1) | TWI764886B (enExample) |
| WO (1) | WO2017158103A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| US9981239B2 (en) | 2015-04-21 | 2018-05-29 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| KR20180050411A (ko) | 2015-09-18 | 2018-05-14 | 트위스트 바이오사이언스 코포레이션 | 올리고핵산 변이체 라이브러리 및 그의 합성 |
| CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
| WO2017095958A1 (en) | 2015-12-01 | 2017-06-08 | Twist Bioscience Corporation | Functionalized surfaces and preparation thereof |
| DK3430030T5 (da) | 2016-03-16 | 2024-09-23 | Immatics Biotechnologies Gmbh | Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| KR102212257B1 (ko) | 2016-08-22 | 2021-02-04 | 트위스트 바이오사이언스 코포레이션 | 드 노보 합성된 핵산 라이브러리 |
| WO2018057526A2 (en) | 2016-09-21 | 2018-03-29 | Twist Bioscience Corporation | Nucleic acid based data storage |
| RS62865B1 (sr) | 2016-12-08 | 2022-02-28 | Immatics Biotechnologies Gmbh | Novi t-ćelijski receptori i imunoterapija u kojoj se koriste |
| DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| EP3554514A4 (en) | 2016-12-16 | 2020-08-05 | Twist Bioscience Corporation | BANKS OF VARIANTS OF IMMUNOLOGICAL SYNAPSE AND THEIR SYNTHESIS |
| CN110892485B (zh) | 2017-02-22 | 2024-03-22 | 特韦斯特生物科学公司 | 基于核酸的数据存储 |
| AU2018234629A1 (en) | 2017-03-15 | 2019-10-17 | Twist Bioscience Corporation | Variant libraries of the immunological synapse and synthesis thereof |
| EP3609530A1 (en) * | 2017-04-10 | 2020-02-19 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| JP7169999B2 (ja) | 2017-06-12 | 2022-11-11 | ツイスト バイオサイエンス コーポレーション | シームレス核酸アセンブリのための方法 |
| AU2018328847A1 (en) | 2017-09-11 | 2020-04-23 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| US11598780B2 (en) * | 2017-10-06 | 2023-03-07 | The University Of Chicago | Engineering lymphocytes with specific alpha and beta chains on their t-cell receptor |
| CA3081336A1 (en) | 2017-10-12 | 2019-04-18 | Gregory LIZEE | T cell receptors for immunotherapy |
| WO2019079769A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | HEATED NANOWELLS FOR THE SYNTHESIS OF POLYNUCLEOTIDES |
| EP4715681A2 (en) | 2018-01-04 | 2026-03-25 | Atlas Data Storage, Inc. | Dna-based digital information storage |
| GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| IL278771B2 (en) | 2018-05-18 | 2025-09-01 | Twist Bioscience Corp | Polynucleotides, reagents and methods for nucleic acid hybridization |
| JP7558151B2 (ja) * | 2018-09-05 | 2024-09-30 | アダプティミューン・リミテッド | Ｔ細胞改変 |
| MA53599A (fr) * | 2018-09-14 | 2021-07-21 | Immatics Biotechnologies Gmbh | Procédé de criblage par affinité peptide-cmh à haut débit destiné à des ligands de tcr |
| DE102018122546B3 (de) | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| CN112912391A (zh) * | 2018-10-25 | 2021-06-04 | 昆士兰医学研究所理事会 | T细胞受体及其用途 |
| GB201819540D0 (en) | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| AU2020227802A1 (en) | 2019-02-26 | 2021-10-14 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| WO2020176678A1 (en) | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN111748028A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111748029B (zh) * | 2019-03-29 | 2022-12-13 | 苏州蓝马医疗技术有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| MX2021013588A (es) * | 2019-05-08 | 2022-02-11 | Medigene Immunotherapies Gmbh | Células t genomodificadas. |
| MA56036A (fr) | 2019-05-27 | 2022-04-06 | Immatics Us Inc | Vecteurs viraux et leur utilisation dans une thérapie cellulaire adoptive |
| CN118994364A (zh) * | 2019-06-18 | 2024-11-22 | 里珍纳龙药品有限公司 | Mage-a4 t细胞受体及其使用方法 |
| EP3986450A4 (en) * | 2019-06-20 | 2023-06-28 | Memorial Sloan Kettering Cancer Center | T cell receptors targeting pik3ca mutations and uses thereof |
| CA3144644A1 (en) | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| CN110357953B (zh) * | 2019-07-17 | 2022-05-03 | 深圳市因诺转化医学研究院 | 识别人巨细胞病毒pp65抗原的TCR |
| WO2021019474A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | Mhc class ii molecules and methods of use thereof |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| BR112022011235A2 (pt) | 2019-12-09 | 2022-12-13 | Twist Bioscience Corp | Bibliotecas de variantes de ácido nucleico para receptores de adenosina |
| AU2021206644A1 (en) * | 2020-01-06 | 2022-07-28 | Memorial Hospital For Cancer And Allied Diseases | Novel dominant negative Fas polypeptides, cells comprising thereof and uses thereof |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| CN113621070A (zh) * | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| US20220056411A1 (en) * | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| JP7644421B2 (ja) * | 2020-10-07 | 2025-03-12 | ダアン バイオセラピュティクス カンパニー、リミテッド | Ｔ細胞受容体、ｔ細胞受容体を含む免疫細胞およびそれを用いる方法｛ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ、ｉｍｍｕｎｅ ｃｅｌｌ ｃｏｍｐｒｉｓｉｎｇ ｔ ｃｅｌｌ ｒｅｃｅｐｔｏｒｓ ａｎｄ ｍｅｔｈｏｄ ｕｓｉｎｇ ｔｈｅ ｓａｍｅ｝ |
| PE20250846A1 (es) | 2020-12-31 | 2025-03-21 | Immatics Us Inc | Polipeptidos cd8, composiciones y metodos de uso de estos |
| DE102021100038A1 (de) | 2020-12-31 | 2022-06-30 | Immatics US, Inc. | Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung |
| CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
| KR20230159851A (ko) * | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| WO2022225836A1 (en) * | 2021-04-21 | 2022-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against ras with q61k mutation |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| CN113337514B (zh) * | 2021-08-05 | 2021-10-29 | 卡瑞济(北京)生命科技有限公司 | Tcr表达构建体以及其制备方法和用途 |
| WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN113773378B (zh) * | 2021-10-14 | 2023-11-03 | 深圳大学总医院 | T细胞受体及其应用 |
| EP4414388A4 (en) * | 2021-11-03 | 2025-10-29 | Curon Biopharmaceutical Shanghai Co Ltd | NEW ANTI-L1CAM ANTIBODY |
| WO2023081461A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| US20250134999A1 (en) | 2022-01-14 | 2025-05-01 | Tune Therapeutics, Inc. | Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation |
| CA3247927A1 (en) | 2022-01-14 | 2023-07-20 | Tune Therapeutics, Inc. | Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression |
| EP4472742A1 (en) * | 2022-02-03 | 2024-12-11 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
| EP4514821A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| IL316515A (en) | 2022-04-28 | 2024-12-01 | Immatics Us Inc | Membrane-bound IL15 CD8 proteins, cells, compositions and methods for their use |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4543911A2 (en) * | 2022-06-24 | 2025-04-30 | Amgen Inc. | Magea4 specific t cell receptors |
| US20260055158A1 (en) * | 2022-08-08 | 2026-02-26 | The University Of North Carolina At Chapel Hill | Bioorthogonal t cell receptor molecules and methods of making and using the same |
| WO2024064642A2 (en) | 2022-09-19 | 2024-03-28 | Tune Therapeutics, Inc. | Compositions, systems, and methods for modulating t cell function |
| WO2025029835A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for modulating il-2 gene expression |
| WO2025029840A1 (en) | 2023-07-31 | 2025-02-06 | Tune Therapeutics, Inc. | Compositions and methods for multiplexed activation and repression of t cell gene expression |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026082746A1 (en) | 2024-10-14 | 2026-04-23 | Immatics Biotechnologies Gmbh | Bispecific molecule formulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| WO2008053573A1 (fr) | 2006-10-30 | 2008-05-08 | National University Corporation Hokkaido University | Remède pour néoplasme malin |
| AU2011304728A1 (en) | 2010-09-20 | 2013-03-14 | Biontech Ag | Antigen-specific T cell receptors and T cell epitopes |
| AU2012236068A1 (en) * | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US20140322344A1 (en) * | 2011-08-31 | 2014-10-30 | National University Corporation Tokyo Medical And Dental University | Vaccine preparation for cancer treatment |
| WO2013057596A1 (en) | 2011-10-21 | 2013-04-25 | Atena Srl | Anatomic cushion accumulator for thermal treatment with heat or cold |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| US10202640B2 (en) * | 2014-05-07 | 2019-02-12 | The Board Of Trustees Of The Leland Stanford Junior University | Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing |
-
2016
- 2016-03-16 GB GBGB1604492.7A patent/GB201604492D0/en not_active Ceased
-
2017
- 2017-03-16 MA MA043720A patent/MA43720A/fr unknown
- 2017-03-16 SG SG11201807868VA patent/SG11201807868VA/en unknown
- 2017-03-16 US US15/460,654 patent/US10538573B2/en active Active
- 2017-03-16 WO PCT/EP2017/056260 patent/WO2017158103A1/en not_active Ceased
- 2017-03-16 CN CN201780017511.6A patent/CN108884136B/zh not_active Expired - Fee Related
- 2017-03-16 KR KR1020217015786A patent/KR102457504B1/ko active Active
- 2017-03-16 MY MYPI2018703216A patent/MY189042A/en unknown
- 2017-03-16 MA MA43330A patent/MA43330B1/fr unknown
- 2017-03-16 TW TW106108700A patent/TWI764886B/zh not_active IP Right Cessation
- 2017-03-16 CA CA3017502A patent/CA3017502A1/en active Pending
- 2017-03-16 JP JP2018548022A patent/JP7340127B2/ja active Active
- 2017-03-16 EP EP17710955.0A patent/EP3430030B1/en active Active
- 2017-03-16 AU AU2017235467A patent/AU2017235467B2/en not_active Ceased
- 2017-03-16 MX MX2018011225A patent/MX2018011225A/es unknown
- 2017-03-16 CR CR20180492A patent/CR20180492A/es unknown
- 2017-03-16 KR KR1020187029016A patent/KR102259109B1/ko not_active Expired - Fee Related
- 2017-03-16 EA EA201892021A patent/EA201892021A1/ru unknown
-
2021
- 2021-07-07 AU AU2021204753A patent/AU2021204753A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201892021A1 (ru) | 2019-02-28 |
| US10538573B2 (en) | 2020-01-21 |
| TWI764886B (zh) | 2022-05-21 |
| JP7340127B2 (ja) | 2023-09-07 |
| CA3017502A1 (en) | 2017-09-21 |
| JP2019511222A (ja) | 2019-04-25 |
| KR20180118783A (ko) | 2018-10-31 |
| MA43330B1 (fr) | 2020-06-30 |
| MA43720A (fr) | 2018-11-28 |
| EP3430030B1 (en) | 2023-12-20 |
| CN108884136B (zh) | 2023-03-17 |
| CR20180492A (es) | 2019-01-31 |
| WO2017158103A1 (en) | 2017-09-21 |
| AU2017235467A1 (en) | 2018-11-01 |
| US20170267738A1 (en) | 2017-09-21 |
| KR102259109B1 (ko) | 2021-06-01 |
| GB201604492D0 (en) | 2016-04-27 |
| AU2021204753A1 (en) | 2021-08-05 |
| TW201736396A (zh) | 2017-10-16 |
| SG11201807868VA (en) | 2018-10-30 |
| KR102457504B1 (ko) | 2022-10-20 |
| EP3430030A1 (en) | 2019-01-23 |
| KR20210063486A (ko) | 2021-06-01 |
| MY189042A (en) | 2022-01-21 |
| MA43330A1 (fr) | 2019-07-31 |
| AU2017235467B2 (en) | 2021-04-08 |
| CN108884136A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018010811A2 (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| CL2023001346A1 (es) | Uso de péptidos en inmunoterapia contra cáncer de pulmón amicrocítico y otros. | |
| CR20180492A (es) | Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer | |
| MX2018011223A (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cancer. | |
| CL2021000980A1 (es) | Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361) | |
| CL2021002459A1 (es) | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| MX2020007808A (es) | Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer. | |
| MX2018005273A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de mama y otos tipos de cancer. | |
| MX2021013147A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres. | |
| MX2018001421A (es) | Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer de prostata y otros tipos de cancer. | |
| MX2018005374A (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer. | |
| MX2017012427A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores. | |
| CR20210234A (es) | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) | |
| MX2017017145A (es) | Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres. | |
| MX2018002480A (es) | Peptidos novedosos, combinacion de peptidos y soportes para usarse en el tratamiento inmunoterapeutico de varios tipos de cancer. | |
| CO2018010808A2 (es) | Linfocitos t transfectados y receptores de linfocito t para el uso en la inmunoterapia contra el cáncer | |
| MX2019012225A (es) | Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer. | |
| MX2019002067A (es) | Nuevos peptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros tipos de cancer. | |
| MX2021001147A (es) | Inmunoterapia con peptidos restringidos a b*07 y una combinacion de peptidos contra el cancer y metodos relacionados. | |
| CL2024000530A1 (es) | Péptidos y combinaciones, su uso en la inmunoterapia contra cáncer de pulmón y otros cánceres | |
| MX2018011220A (es) | Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer. | |
| CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| MX2021003089A (es) | Inmunoterapia con peptidos restringidos a a*01 y una combinacion de peptidos contra el cancer y metodos relacionados. | |
| CO2020013659A2 (es) | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CO2019012071A2 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer |